Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature

Blood

Volumn 101, Issue 5, 2003, Pages 1827-1832

  Galli, Monica ^a   Luciani, Davide ^b   Bertolini, Guido ^b   Barbui, Tiziano ^b  

^a OSPEDALI RIUNITI   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT;

ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 0037370733     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0441     Document Type: Article

References (58)

1. Mackie JI, Donohoe S, Machin SJ. Lupus anticoagulant measurement. In: Khamashta MA (ed). Hughes Syndrome. Antiphospholipid Syndrome. London, England; Springer; 2000:214-224.
2. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay: standardization and quantitation of results. Clin Exp Immunol. 1985;62:739-744.
3. McNeil HP, Simpson RJ, Chesterman CN, Krills SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87:4120-4124.
4. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 1990;334:1544-1547.
5. Arvieux J, Darnige L, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost. 1995;74:1120-1125.
6. Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM. Anticoagulant activity of β 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost. 1992;68:297-300.
7. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997;77:486-491.
8. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The "primary" antiphospholipid syndrome; major clinical and serological features. Medicine. 1989;68:366-374.
9. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L. Antiphospholipid antibodies and the antiphospholipid syndrome in SLE. A prospective analysis of 500 consecutive patients. Medicine. 1989;68:353-365.
10. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum. 1999;42:1309-1311.
11. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research. New York, NY: Van Nostrand Reinhold; 1982:58-59.
12. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995;74:1185-1190.
13. Pierangeli SS, Gharavi AE, Harris EN. Anticardiolipin testing. In: Khamashta MA (ed). Hughes Syndrome. Antiphospholipid Syndrome. London, England: Springer; 2000:205-213.
14. Finazzi G, Cortelazzo S, Galli M, Barbui T. Relative risk of recurrent abortion and thrombosis in young subjects with antiphospholipid antibodies estimated by case-control studies [abstract]. Postgrad Med J. 1989;65:697.
15. Barbui T, Finazzi G, Cortelazzo S, Galli M, Camerlingo M. A case-control estimate of the relative risk of cerebral ischaemic disease in young subjects with antiphospholipid antibodies [abstract]. Thromb Haemost. 1989;62:584.
16. Stegnar M, Bozic B, Peternel P, Kveder T, Vene N, Rozman B. Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis. Thromb Res. 1991;63:433-443.
17. Hess DC, Krauss J, Adams RJ, Nichols FT, Zhang D, Rountree HA, Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology. 1991;41:525-528.
18. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117:997-1002.
19. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993;43:2069-2073.
20. Camerlingo M, Casto L, Drago G, et al. Anticardiolipin antibodies in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand. 1995;92:69-71.
21. Vaarala O, Manttari M, Manninen V, et al. Anticardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995;91:23-27.
22. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythematosus patients: a controlled prospective study. Am J Med. 1996;171;381-386.
23. Wu R, Nytianand S, Berglund L, Lithell L, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997;17:3159-3163.
24. Tuhrim S, Rand JH, Wu X-X, et al. Elevated anticardiolipin antibody titer is a strong risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. 1999;30:1561-1565.
25. Bongard O, Reber G, Bounameaux H, De Moerloose P. Anticardiolipin antibodies in acute venous thromboembolism [letter]. Thromb Haemost 1992;67:724.
26. Simioni P, Prandoni P, Zanon E, et al. Deep venous thrombosis and lupus anticoagulant. A case-control study. Thromb Haemost. 1996;76:187-189.
27. Oger E, Leroyer C, Dueymes M, et al. Association between IgM anticardiolipin antibodies and deep vein thrombosis in patients without systemic lupus erythematosus. Lupus. 1997;6:455-461.
28. Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke. 1992;23:189-193.
29. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86:3685-3691.
30. Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol. 1995;38:119-124.
31. Abu-Shakra M, Gladman DD, Urowitz MB, Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med. 1995;99:624-628.
32. Prandoni P, Simioni P, Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation [letter]. Thromb Haemost. 1996;75:859.
33. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med. 1996;100:530-536.
34. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996;348:1120-1124.
35. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke. 1997;28:1660-166.
36. Rance A, Emmerich J, Fiessinger J-N. Anticardiolipin antibodies and recurrent thromboembolism [letter]. Thromb Haemost. 1997;77:221.
37. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998;104:332-338.
38. De Bandt M, Benali K, Guillevin L, et al. Longitudinal determination of antiphosphoJipid antibodies in lupus patients without previous manifestations of antiphospholipid syndrome. A prospective study. J Rheumatol 1999;26:91-96.
39. Rosove MH, Brewer PMC. Antiphospholipid antibodies and thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303-308.
40. Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphosphoJipid syndrome: a European multicenter study of 114 patients. Am J Med. 1994;96:3-9.
41. Derksen RHWM, de Groot P, Kater L, Nieuwenhuis HK. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis. 1993;52:689-692.
42. Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus, 1998;7:3-6.
43. Galli M, Finazzi G, Norbis F, Marziali S, Marchioli R, Barbui T. The risk of thrombosis in patients with lupus anticoagulants is predicted by their specific coagulation profile. Thromb Haemost. 1999;81:695-700.
44. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993-997.
45. Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J, Alarcon-Segovia D. Influence of disease duration, continued followup and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus. J Rheumatol. 1993;20:437-442.
46. Kushner MJ. Prospective study of anticardiolipin antibodies in stroke. Stroke. 1990;21:295-298.
47. Greenhalgh T. How to read a paper. Getting your bearings (deciding what the paper is about). BMJ. 1997;315:243-246.
48. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
49. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. Thromb Haemost. 1995;74:1597-1603.
50. Roussi J, Roisin JP, Goguel A. Lupus anticoagulants: first French interlaboratory Etalonorme survey. Am J Clin Pathol. 1996;105:788-793.
51. Jennings I, Kitchen S, Woods TAL, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost. 1997;77:934-937.
52. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human β2-glycoprotein I. Thromb Haemost. 1999;81:929-934.
53. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk of venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus. Lupus. 1997;6:467-473.
54. Wahl DG, Guillemin F, de Maistre E, Perret-Guillaume C, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus. 1998;7:15-22.
55. Martinelli I, Mannucci PM, De Stefano V, et al. Different risk of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998;92;2353-2358.
56. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations. Thromb Haemost. 2001;86:575-583.
57. Ward AM, White PAE. Measuring anticardiolipin antibodies. BMJ. 1995;310:1472-1473.
58. Giordano P, Galli M, Del Vecchio GC, et al, Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassemia. Br J Haematol. 1998;102:903-906.